CVRX
CVRx, Inc.
$5.40
+0.37%
$138.0M
No data for this timeframe.
Vol
Market Cap$138.0M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders7 funds
Inst. Value$11.6M
Inst. Activity1 buys / 2 sells
Insider Activity1B / 5S
Insider Net $$171.0K
SEC Reports10
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001235912·Prev Close $5.38
Recent Activity
Jun 9, 2026
SEC
CFO Jared Oasheim has resigned to pursue other opportunities, effective upon appointment of a successor. He will remain
8-K — Impact 3/10
Jun 9, 2026
SEC
CVRx reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with revenue of $15.6M in line with estimates.
PRESS-RELEASE — Impact 5/10
Jun 3, 2026
SEC
Michael D. Dale filed a Form 3 initial statement of beneficial ownership with the SEC, indicating he has become an offic
3 — Impact 2/10
Jun 1, 2026
Insider
Nielsen Kirk G. sold 8,720 shares
Director @ $0.00 ($0.00)
Jun 1, 2026
Insider
Jain Mudit K. sold 11,182 shares
Director @ $0.00 ($0.00)
Jun 1, 2026
Insider
Jain Mudit K. sold 8,720 shares
Director @ $0.00 ($0.00)
Inst.
BANK OF AMERICA CORP — NEAR_EXIT
44,494 shares ($315.9K)
Inst.
TWO SIGMA INVESTMENTS, LP — TRIM
24,456 shares ($173.6K)
Price Targets
$11.17
+114.7% upside
Strong Buy
Current $5.20
Low $6.00
Median $12.00
High $14.00
6 analysts
$6.00
$14.00
Analyst Ratings
3Strong Buy
8Buy
1Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 14, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Feb 13, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.52 ▼ -1.1% | $-0.57 — $-0.46 | 8% YoY | 7 |
| Next Q | $-0.48 ▼ -1.3% | $-0.56 — $-0.41 | 1% YoY | 7 |
| Current FY | $-1.96 ▲ +0.7% | $-2.13 — $-1.74 | 4% YoY | 7 |
| Next FY | $-1.89 ▼ -1.4% | $-2.17 — $-1.42 | 3% YoY | 7 |
Latest Reports
NEUTRAL
8-K
3/10
CFO Jared Oasheim has resigned to pursue other opportunities, effective upon appointment of a successor. He will remain
Jun 9, 2026
NEUTRAL
PRESS-RELEASE
5/10
CVRx reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with revenue of $15.6M in line with estimates.
Jun 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $8.0M | — |
| MORGAN STANLEY | $2.7M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $326.2K | NEW |
| BANK OF AMERICA CORP | $315.9K | NEAR_EXIT |
| TWO SIGMA INVESTMENTS, LP | $173.6K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | Nielsen Kirk | A | $0.00 |
| Jun 1, 2026 | Jain Mudit | A | $0.00 |
| Jun 1, 2026 | Jain Mudit | A | $0.00 |
| Jun 1, 2026 | Ballinger Kevin | A | $0.00 |
| Jun 1, 2026 | SHADAN MARTHA | A | $0.00 |
7 institutional holders with $11.6M total value (1,636,762 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,120,663 | $8.0M | 68.5% | — |
| 2 | MORGAN STANLEY | 380,641 | $2.7M | 23.3% | ADD +85.0% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 45,941 | $326.2K | 2.8% | NEW |
| 4 | BANK OF AMERICA CORP /DE/ | 44,494 | $315.9K | 2.7% | NEAR_EXIT -75.3% |
| 5 | TWO SIGMA INVESTMENTS, LP | 24,456 | $173.6K | 1.5% | TRIM -30.9% |
| 6 | WELLS FARGO & COMPANY/MN | 20,266 | $143.9K | 1.2% | ADD +61.3% |
| 7 | FMR LLC | 301 | $2.1K | 0.0% | NEAR_EXIT -93.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 180,425 | 44,494 | -75.3% | $315.9K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 35,390 | 24,456 | -30.9% | $173.6K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 12,561 | 20,266 | +61.3% | $143.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 89,049 | 180,425 | +102.6% | $1.5M | 2025-Q3 |
| UBS Group AG | ADD | 88,144 | 151,323 | +71.7% | $1.2M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 87,591 | 35,390 | -59.6% | $285.6K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 14,000 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | ADD | 199,005 | 368,251 | +85.0% | $2.2M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 147,128 | 87,591 | -40.5% | $515.0K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 14,000 | — | $82.3K | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 4,326 | 264 | -93.9% | $1.6K | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 72,100 | 318,443 | +341.7% | $3.9M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 55,367 | 147,128 | +165.7% | $1.8M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 40,200 | 0 | -100.0% | $0.00 | 2025-Q1 |
| NORGES BANK | EXIT | 111,400 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 25,159 | 73,911 | +193.8% | $936.5K | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 127,028 | 72,100 | -43.2% | $913.5K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 40,200 | — | $509.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 4,779 | 8,894 | +86.1% | $112.7K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 37,154 | — | $327.3K | 2024-Q3 |
14 unique insiders with 6 transactions. Net insider value: $171.0K ($297.6K bought, $126.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | Nielsen Kirk G. | Director | A | 8,720 | $0.00 | $0.00 |
| Jun 1, 2026 | Jain Mudit K. | Director | A | 11,182 | $0.00 | $0.00 |
| Jun 1, 2026 | Jain Mudit K. | Director | A | 8,720 | $0.00 | $0.00 |
| Jun 1, 2026 | Ballinger Kevin J. | Director | A | 11,182 | $0.00 | $0.00 |
| Jun 1, 2026 | SHADAN MARTHA | Director | A | 8,720 | $0.00 | $0.00 |
| Jun 1, 2026 | Hill, Mitch C. | Director | A | 11,182 | $0.00 | $0.00 |
| Jun 1, 2026 | SLATTERY JOSEPH P | Director | A | 11,182 | $0.00 | $0.00 |
| Jun 1, 2026 | Nielsen Kirk G. | Director | A | 11,182 | $0.00 | $0.00 |
| Jun 1, 2026 | SLATTERY JOSEPH P | Director | A | 8,720 | $0.00 | $0.00 |
| Jun 1, 2026 | DALE MICHAEL D | Director | A | 36,252 | $0.00 | $0.00 |
| Jun 1, 2026 | Ballinger Kevin J. | Director | A | 8,720 | $0.00 | $0.00 |
| Jun 1, 2026 | DALE MICHAEL D | Director | A | 29,005 | $0.00 | $0.00 |
| Jun 1, 2026 | SHADAN MARTHA | Director | A | 11,182 | $0.00 | $0.00 |
| Jun 1, 2026 | Hill, Mitch C. | Director | A | 8,720 | $0.00 | $0.00 |
| Mar 2, 2026 | VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER | SELL | 1,284 | $7.90 | $10.1K |
| Mar 2, 2026 | OASHEIM JARED | CHIEF FINANCIAL OFFICER | SELL | 1,744 | $7.90 | $13.8K |
| Mar 2, 2026 | Morrison Gregory | CHIEF HUMAN RESOURCES OFFICER | A | 34,000 | $0.00 | $0.00 |
| Mar 2, 2026 | Hykes Kevin | PRES & CEO | SELL | 7,763 | $7.90 | $61.3K |
| Mar 2, 2026 | Morrison Gregory | CHIEF HUMAN RESOURCES OFFICER | A | 154,500 | $0.00 | $0.00 |
| Mar 2, 2026 | Adamson Philip B. | Chief Medical Officer | SELL | 1,262 | $7.90 | $10.0K |
| Mar 2, 2026 | John Robert Allen | Chief Revenue Officer | SELL | 3,964 | $7.90 | $31.3K |
| Feb 27, 2026 | John Robert Allen | Chief Revenue Officer | A | 35,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Binkowski Brent | CHIEF OPERATING OFFICER | A | 23,000 | $0.00 | $0.00 |
| Feb 27, 2026 | VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER | A | 45,000 | $0.00 | $0.00 |
| Feb 27, 2026 | OASHEIM JARED | CHIEF FINANCIAL OFFICER | A | 61,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Binkowski Brent | CHIEF OPERATING OFFICER | A | 15,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Hykes Kevin | PRES & CEO | A | 159,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Hykes Kevin | PRES & CEO | A | 238,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Adamson Philip B. | Chief Medical Officer | A | 62,000 | $0.00 | $0.00 |
| Feb 27, 2026 | Adamson Philip B. | Chief Medical Officer | A | 41,000 | $0.00 | $0.00 |
| Feb 27, 2026 | John Robert Allen | Chief Revenue Officer | A | 52,000 | $0.00 | $0.00 |
| Feb 27, 2026 | VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER | A | 67,000 | $0.00 | $0.00 |
| Feb 27, 2026 | OASHEIM JARED | CHIEF FINANCIAL OFFICER | A | 91,000 | $0.00 | $0.00 |
| Feb 20, 2026 | Jain Mudit K. | Director | BUY | 46,800 | $6.36 | $297.6K |
10 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 8 neutral. Avg impact: 3.8/10.
NEUTRAL
8-K
3/10
CFO Jared Oasheim has resigned to pursue other opportunities, effective upon appointment of a succes
Jun 9, 2026
NEUTRAL
PRESS-RELEASE
5/10
CVRx reported Q1 2026 EPS of -$0.50, beating consensus of -$0.52 by 4.5%, with revenue of $15.6M in
Jun 9, 2026
NEUTRAL
3
2/10
Michael D. Dale filed a Form 3 initial statement of beneficial ownership with the SEC, indicating he
Jun 3, 2026
NEUTRAL
8-K
5/10
CVRx reported Q1 2026 revenue of $14.8M (+20% YoY), in line with the preliminary range, and a net lo
May 11, 2026
NEUTRAL
PRESS-RELEASE
2/10
CVRx announced it will release Q1 2026 financial results after market close on May 11, 2026, with a
Apr 27, 2026
BULLISH
8-K
8/10
CVRx reported preliminary Q1 2026 revenue of $14.7–14.8 million (approximately 20% YoY growth) and r
Apr 21, 2026
NEUTRAL
DEFA14A
2/10
CVRx, Inc. filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting. The fi
Apr 20, 2026
NEUTRAL
CLUSTER
3/10
Analysis based on filing metadata only — document content was unavailable. The filing indicates an i
Mar 16, 2026
BEARISH
CLUSTER
5/10
Multiple C-suite executives at CVRx, including the CEO, CFO, and CRO, conducted open-market share sa
Mar 4, 2026
NEUTRAL
CLUSTER
3/10
Three CVRX executives — CFO, CRO, and COO — received non-cash stock awards totaling 111,000 shares,
Mar 3, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 3 strong buy, 8 buy, 1 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$11.17 mean target
+114.7% upside
Strong Buy (1.57)
$6.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $5.20 |
| Target Low | $6.00 |
| Target Mean | $11.17 |
| Target Median | $12.00 |
| Target High | $14.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.57) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.52 | $-0.57 | $-0.46 | 8.1% | -1.1% | 4↑ 1↓ | $0.0B | 14.4% | 7 |
| Next Q 2026-09-30 |
$-0.48 | $-0.56 | $-0.41 | 1.2% | -1.3% | 2↑ 1↓ | $0.0B | 14.6% | 7 |
| Current FY 2026-12-31 |
$-1.96 | $-2.13 | $-1.74 | 3.8% | +0.7% | 5↑ 0↓ | $0.1B | 15.2% | 7 |
| Next FY 2027-12-31 |
$-1.89 | $-2.17 | $-1.42 | 3.5% | -1.4% | 1↑ 4↓ | $0.1B | 16.7% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.524 | |
| 7d ago | $-0.524 | |
| 30d ago | $-0.518 | -0.006 |
| 60d ago | $-0.522 | -0.002 |
| 90d ago | $-0.522 | -0.002 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 14, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 13, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 8 | 1 | 1 | 0 | 85% | |
| May 1, 2026 | 3 | 8 | 1 | 1 | 0 | 85% | |
| Apr 1, 2026 | 3 | 8 | 1 | 1 | 0 | 85% | |
| Mar 1, 2026 | 3 | 8 | 1 | 1 | 0 | 85% | |
| Feb 1, 2026 | 3 | 8 | 1 | 1 | 0 | 85% | |
| Jan 1, 2026 | 3 | 8 | 1 | 1 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
earnings
CVRx Announces Chief Financial Officer Transition
<p>MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developin
May 27, 2026
other
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
<p>MINNEAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing
May 20, 2026
other
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
<p>MINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing
May 14, 2026
other
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
<p>MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing
May 11, 2026
earnings_calendar
CVRX Q1 2026 Earnings After Market Close — 2026-05-11
May 4, 2026
fda
CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population
<p align="left">MINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturi
Apr 29, 2026
earnings_calendar
CVRX Q1 2026 Earnings After Market Close — 2026-04-29
Apr 27, 2026
earnings
CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026
<p>MINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developi
Apr 20, 2026
routine
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
<p align="left">MINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufactu
Mar 2, 2026
routine
CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting
<p align="left">MINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufactu